Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

**General description**
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

**INN** | Bevacizumab
---|---
**ATC codes** | S01LA08
**Medicine type** | Biological agent
**EML status history** | First added in 2013 (TRS 985) for Age related macular degeneration
**Wikipedia** | Bevacizumab
**DrugBank** | Bevacizumab

**Recommended**

**Section**
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

**Indications**
Age related macular degeneration